Patents Assigned to Daiichi Sankyo Company, Limited
  • Patent number: 10351624
    Abstract: It is intended to provide a therapeutic and/or prophylactic agent for transplant rejections, immunological diseases, allergic diseases, inflammatory diseases, thrombosis, cancers, etc., targeting human Orai1. The present invention provides, for example, a pharmaceutical composition comprising an antibody that specifically recognizes human Orai1 and has the activity of inhibiting human T cell activation.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: July 16, 2019
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Tomoaki Komai, Takako Kimura, Daichi Baba, Yoshikuni Onodera, Kento Tanaka, Takashi Kagari, Anri Aki, Nobumi Nagaoka
  • Publication number: 20190202911
    Abstract: To provide a novel antibody. Provided is a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.
    Type: Application
    Filed: September 7, 2017
    Publication date: July 4, 2019
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Ryuta Mukasa, Kensuke Nakamura, Sumie Muramatsu, Naoyuki Makita
  • Publication number: 20190201386
    Abstract: The present invention provides a method for treating a cancer in a subject in need thereof, comprising administering a specific MDM2 inhibitor to the subject according to a specific dosage regimen and a pharmaceutical composition for use in treating a cancer according to the dosage regimen. The present invention also provides a method for treating liposarcoma in a subject in need thereof, comprising administering a specific MDM2 inhibitor to the subject and a pharmaceutical composition for use in treating liposarcoma, comprising the MDM2 inhibitor.
    Type: Application
    Filed: March 6, 2019
    Publication date: July 4, 2019
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Ngai-chiu Archie TSE, Shengli CAI
  • Publication number: 20190203304
    Abstract: It is intended to develop a therapeutic strategy for specifically targeting cancer cells having the functional suppression of PSS2. The present inventors have found that PSS1 and PSS2 are in a synthetic lethal relationship, and treatment inhibiting PSS1 serves as a promising approach for the treatment of cancer having the functional suppression of PSS2. It has also been revealed that this therapeutic strategy permits efficient treatment based on companion diagnostics because a PSS1 inhibitor can be administered to a subject selected by using the functional suppression of PSS2 as an index.
    Type: Application
    Filed: March 15, 2019
    Publication date: July 4, 2019
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yohei YOSHIHAMA, Tatsuya INOUE
  • Publication number: 20190175551
    Abstract: Provided is a pharmaceutical composition for treating a renal disease. The pharmaceutical composition for treating a renal disease comprises a mineralocorticoid receptor antagonist.
    Type: Application
    Filed: September 20, 2018
    Publication date: June 13, 2019
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Kiyoshi Arai, Tsuyoshi Homma, Tomoko Sawanobori, Shin Nakajima, Rie Hisatomi, Motonobu Yoshimura
  • Patent number: 10316026
    Abstract: In a method for producing a de-dimethoxybenzylated compound by removing a dimethoxybenzyl group from a compound containing a dimethoxybenzyl group bonded to a nitrogen atom in the presence of an acid, the de-dimethoxybenzylated compound is obtained by removing the dimethoxybenzyl group without forming a poorly soluble product resulting from the removed dimethoxybenzyl group. The de-dimethoxybenzylation reaction is carried out in the presence of triphenylphosphine or diethylthiourea.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: June 11, 2019
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kohei Kadota, Tsuyoshi Ueda
  • Publication number: 20190169293
    Abstract: The present invention provides a conjugate comprising a hANP peptide bonded via a polyethylene glycol linker to a glycan attached to Asn297 of a Fc-containing molecule (N297 glycan), or a pharmaceutically acceptable salt thereof, a medicament comprising the same as an active ingredient, a method for producing the same, etc.
    Type: Application
    Filed: June 30, 2017
    Publication date: June 6, 2019
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Mitsuhiro IWAMOTO, Shohei OISHI, Yukiko SEKIGUCHI, Hiroyuki CHAYA, Ryuki MIYAUCHI, Takeshi HONDA
  • Patent number: 10308604
    Abstract: The present invention provides a method for producing an atropisomer of a pyrrole derivative having excellent mineralocorticoid receptor antagonistic activity, and an intermediate thereof. A method for producing an atropisomer of a pyrrole derivative using a compound represented by (B) [wherein R1 represents a C1-C4 alkyl group, and R2 represents a 2-hydroxyethyl group or a carboxymethyl group] as a production intermediate.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: June 4, 2019
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Masashi Watanabe, Hiroshi Nagasawa, Noritada Sato
  • Patent number: 10308612
    Abstract: A method for producing a 1-(acyloxy)alkyl carbamate derivative (III), using a fluorous alkyl carbonate derivative (I), and a fluorous alkyl carbonate derivative (I) and a method for producing the same. In the formula, R1 represents C1-C4 alkyl group or a C3-C6 cycloalkyl group, R2 represents a C1-C4 alkyl group or a hydrogen atom, and A represents a fluorous alkyl group (wherein the fluorous alkyl group represents a C2-C11 alkyl group in which 40% or more of the hydrogen atoms are replaced by fluorine atoms).
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: June 4, 2019
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Tsuyoshi Ueda, Yuzo Abe
  • Patent number: 10308715
    Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: June 4, 2019
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoshiharu Hiruma, Eisuke Tsuda
  • Publication number: 20190151328
    Abstract: To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— or -L1-L2-LP- (the anti-HER3 antibody is connected to the terminal of L1, the antitumor compound is connected to the carbonyl group of —(CH2)n2-C(?O)— moiety or the C terminal of LP, with the nitrogen atom of the amino group at position 1 as a connecting position).
    Type: Application
    Filed: January 31, 2019
    Publication date: May 23, 2019
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, DAIICHI SANKYO EUROPE GMBH
    Inventors: Thore HETTMANN, Reimar ABRAHAM, Sabine BLUM, Suguru UENO
  • Publication number: 20190144559
    Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.
    Type: Application
    Filed: January 24, 2019
    Publication date: May 16, 2019
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, SAPPORO MEDICAL UNIVERSITY
    Inventors: Toshinori Agatsuma, Shu Takahashi, Jun Hasegawa, Daisuke Okajima, Hirofumi Hamada, Miki Yamaguchi
  • Publication number: 20190117624
    Abstract: A therapeutic agent for inflammatory bowel diseases comprising as an active ingredient a compound represented by the formula (I) wherein R represents a hydrogen atom or a [1-(isobutyryloxy)ethoxy]carbonyl group or the like, or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: March 28, 2017
    Publication date: April 25, 2019
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kengo NOGUCHI, Yusuke ITO
  • Patent number: 10266871
    Abstract: It is an object of the present invention to provide a measurement method capable of easily evaluating combined effects in a single assay system, when antithrombotic agents having different mechanisms of action are used in combination. A method for measuring thrombin generation comprising: (1) a step of adding an anticoagulant, a P2Y12 receptor inhibitor, adenosine diphosphate and tissue factor to platelet rich plasma; (2) a step of adding a fluorogenic thrombin substrate and a calcium-containing solution thereto; and (3) a step of measuring fluorescence intensity.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: April 23, 2019
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yoshiyuki Morishima, Yuko Honda
  • Publication number: 20190112606
    Abstract: The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3?-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and ?-1,3-glucan.
    Type: Application
    Filed: December 20, 2018
    Publication date: April 18, 2019
    Applicants: NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Ken ISHII, Kouji KOBIYAMA, Taiki AOSHI, Fumihiko TAKESHITA, Yuji KASUYA, Takako NIWA, Makoto KOIZUMI
  • Patent number: 10253060
    Abstract: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: April 9, 2019
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Satoshi Komoriya, Yasuhiro Nakagami, Emiko Hatano, Takashi Ohnuki, Kayoko Masuda, Mayumi Iizuka, Yasunori Ono
  • Publication number: 20190092741
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.
    Type: Application
    Filed: March 29, 2017
    Publication date: March 28, 2019
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
  • Publication number: 20190077880
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.
    Type: Application
    Filed: September 13, 2018
    Publication date: March 14, 2019
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Hiroyuki NAITO, Yusuke OGITANI, Takeshi MASUDA, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Koji MORITA, Hideki MIYAZAKI, Yuji KASUYA, Ichiro HAYAKAWA, Yuki ABE
  • Patent number: 10227417
    Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: March 12, 2019
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, SAPPORO MEDICAL UNIVERSITY
    Inventors: Toshinori Agatsuma, Shu Takahashi, Jun Hasegawa, Daisuke Okajima, Hirofumi Hamada, Miki Yamaguchi
  • Patent number: 10221195
    Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I): wherein R1 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R2 and R3 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R4 and R5 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R6 represents a hydrogen atom or the like, each R7 may be the same or different and may each represent an optionally substituted C1-6 alkoxy group or the like, X represents —CH?, —C(—R7)?, or —N?, and m represents 1 to 4, or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: March 5, 2019
    Assignees: Daiichi Sankyo Company, Limited, Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Shojiro Miyazaki, Yuko Yamamoto, Keisuke Suzuki, Masaharu Inui, Masanori Izumi, Kaori Soma, Anthony Pinkerton, Taeko Shinozaki